Balang, Kemberly G.
HRN: 22-89-65 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/01/2024
CEFOTAXIME 500MG (VIAL)
11/01/2024
11/07/2024
PO
500 Mg
BID
UTI
Waiting Final Action
Indication: EmpiricEmpirical De-escalation Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes